Abstract
Because of their low incidence of adverse effects SSRI are prescribed more and more frequently in patients with depressive disorders. SSRI inhibit different subsystems of cytochrome-P 450-oxydase. Especially during co-administration of SSRI with antipsychotic and antiarrhythmic drugs pharmacokinetic interactions have to be observed carefully. In this presentation a case of bradycardia after co-administration of paroxetine and metoprolol is reported. Drug history and a careful drug monitoring are necessary requirements to avoid serious adverse effects.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / adverse effects*
-
Antidepressive Agents, Second-Generation / administration & dosage
-
Antidepressive Agents, Second-Generation / adverse effects*
-
Blood Pressure / drug effects
-
Bradycardia / chemically induced*
-
Bradycardia / diagnosis
-
Cardiomyopathy, Hypertrophic / drug therapy*
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / psychology
-
Drug Therapy, Combination
-
Electrocardiography / drug effects
-
Female
-
Heart Rate / drug effects
-
Humans
-
Lithium Carbonate / administration & dosage
-
Lithium Carbonate / adverse effects
-
Metoprolol / administration & dosage
-
Metoprolol / adverse effects*
-
Middle Aged
-
Paroxetine / administration & dosage
-
Paroxetine / adverse effects*
Substances
-
Adrenergic beta-Antagonists
-
Antidepressive Agents, Second-Generation
-
Lithium Carbonate
-
Paroxetine
-
Metoprolol